Dr. Michael Rezak, MD, PhD

Dr. Rezak practices at United Therapies - Park Ridge in Park Ridge, Illinois.

Dr. Rezak's NPI, 1003975897, was assigned on December 7, 2006. Dr. Rezak graduated from Loyola University of Chicago, Stritch School of Medicine in 1985. Dr. Rezak holds Illinois license 036073545.

Dr. Rezak's primary practice is United Therapies - Park Ridge, at 1875 W Dempster St, Park Ridge, IL 60068. The practice phone is (847) 544-5853.

Dr. Rezak's primary practice is United Therapies - Park Ridge in Park Ridge, Illinois. Dr. Rezak is also affiliated with Advocate Lutheran General Hospital. The medical group on file is Dreyer Medical Clinic (Advocate Medical Group). Dmand AI also links Dr. Rezak to 2 more hospitals, 2 group practices and clinics, 2 medical groups and 1 home health agency, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Rezak practices, 7 sites in all. Vendor and product names are available with a free account.

Neurology is Dr. Rezak's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dmand AI has Dr. Rezak's licenses on file in 3 states: Illinois, Connecticut and New York.

CMS data shows 8,100 Medicare services from Dr. Rezak across 7 procedure codes in 2024, for 225 Medicare patients. Medicare paid $80,891 for them. Every service was in an office.

CMS counts 225 Medicare patients who saw Dr. Rezak in 2024. The largest group is 75 to 84, with 117 patients. 75% of them have high cholesterol, and 73% have high blood pressure. 11% are also on Medicaid. Their average risk score is 1.58, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Rezak's median patient age at 76, with 40% women.

In 2024, Dr. Rezak wrote 2,462 Medicare Part D claims for 304 patients. 83% of them were for generic drugs. CMS names the drug for 2,320 of them, across 39 drugs with 11 or more claims each, at $1,428,366 in total drug cost. In 2023, CMS named 2,427 claims across 42 drugs.

Dr. Rezak accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Rezak as offering telehealth.

Dmand AI links 9 papers to Dr. Rezak, published from 2010 to 2020. 2010 was the busiest year, with 2. The most frequent topics are Parkinson Disease, Ubiquitin-Protein Ligases and Age of Onset. Dr. Rezak has published most often in Neurology. Dr. Rezak's most frequent co-authors are Roy Nissim Alcalay, MD, Susan B. Bressman, MD and Cynthia L. Comella, MD.

CMS Open Payments shows 624 general payments to Dr. Rezak from 19 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 61% of the total. ACADIA Pharmaceuticals Inc paid the most, $100,364.

Dr. Rezak graduated from Loyola University of Chicago, Stritch School of Medicine in 1985.